ADVERTISEMENT
Business
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
In a video interview, Wockhardt chairman Habil Khorakiwala talks about global commercial and manufacturing plans for superbug-busting novel antibiotics and developments such as proposed US tariffs and the Windsor framework that could impact its markets.
US President Trump’s plan for a “25% or higher” tariff on pharmaceuticals promises to have a far-reaching impact, from higher prices and drug shortages to increased onshoring of manufacturing in the US. Is MAGA worth the chaos it might create for MAHA? The Indian industry shares its views.
Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.
In Sept 2024, a new CMDO, DMX Pharma, emerged on the global market. Explore the benefits of this merger, from production capacity to cross-selling capability, regulatory expertise and their ambitious future plans.
Both companies are seeking to license their products as they try to stretch their dwindling cash.